checkAd

     105  0 Kommentare ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024

    ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced that it will hold a conference call on Wednesday, May 8, 2024 at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2024. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.

    Investor Conference Call:

    ChromaDex management will host an investor conference call to discuss the first quarter 2024 results and provide a general business update on Wednesday, May 8, at 4:30 p.m. ET. Participants should call in at least 10 minutes prior to the call. The dial-in information is as follows:

    Date: Wednesday, May 8, 2024
    Time: 4:30 p.m. ET (1:30 p.m. PT)
    Toll-free dial-in number: 1-888-596-4144
    Conference ID: 8584242
    Webcast link: ChromaDex First Quarter 2024 Earnings Conference Call

    The conference call will be broadcast live and available for replay here and via the investor relations section of the Company’s website at www.chromadex.com.

    A replay of the conference call will be available from 7:30 p.m. ET on May 8, 2024, to 11:59 p.m. ET on May 15, 2024. The replay dial-in information is as follows:

    Toll-free replay number: 1-800-770-2030
    Replay ID: 8584242

    About ChromaDex:

    ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, comprised of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality. Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, NIAGEN (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available.

    Seite 1 von 3



    Business Wire (engl.)
    0 Follower
    Autor folgen

    ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced that it will hold a conference call on Wednesday, May 8, 2024 at 4:30 p.m. ET to discuss its financial results for …

    Schreibe Deinen Kommentar

    Disclaimer